The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype

AIDS. 2013 Jan 28;27(3):484-5. doi: 10.1097/QAD.0b013e32835a9a0d.

Abstract

Positive HLA-B*5701 genotype has recently been identified as the main genetic risk factor for flucloxacillin drug-induced liver injury (DILI). Testing for HLA-B*5701 is routine in many HIV clinics to identify those at risk of hypersensitivity reaction (HSR) to abacavir. Considering the high prevalence of soft-tissue infections in HIV patients, we conducted a retrospective study to investigate whether flucloxacillin use was associated with adverse events in HIV patients known to be HLA-B*5701 positive.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Chemical and Drug Induced Liver Injury / etiology*
  • Chemical and Drug Induced Liver Injury / genetics
  • Chemical and Drug Induced Liver Injury / immunology
  • Drug Hypersensitivity / genetics
  • Drug Hypersensitivity / immunology
  • Female
  • Floxacillin / administration & dosage
  • Floxacillin / adverse effects*
  • Genotype
  • HIV Infections / drug therapy
  • HIV Infections / genetics
  • HIV Infections / immunology*
  • HLA-B Antigens / drug effects*
  • HLA-B Antigens / genetics
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors

Substances

  • Anti-Bacterial Agents
  • Anti-HIV Agents
  • HLA-B Antigens
  • HLA-B*57:01 antigen
  • Floxacillin